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Abstract 
The National Institute of Environmental Health Sciences (NIEHS) reports that the Federal 
government has documented over I 0,500 ingredients in cosmetic products ( e;g., skin 
moisturizers, shampoos, perfumes, eye and facial makeup preparations,toothpaStes, deodorants, 
etc.), yet only a small percentage of those chemicals have been tested for safety. Some of the 
~ ''," ,, '',' 
tested chemicals have been identified as causes of cancer, birth: defects, and damllge to one's 
ability to reproduce (EHP, 2006, p. 5). The Environmental Work Group, Campaign for Safe 
Cosmetics and similar non-profit coalitions have campaigned for consumer protection against the 
.· 
dangerous chemicals found in cosmetics. J;hese. organizations conduct research and/or advocate 
•'<'', ',- -, '>-' ' 
for safe products, and inform the general puhl{c Ofthe possi~le harmful effects of chemicals. 
They seek local, state and national supportfrom corporations, federal regulatory agencies and the 
legislative bodies of governmeJi!tto implement changes that would require manufacturers to 
disclose chemicals.use.d in c()~fuetic products, use safe alternative ingredients, and to reduce the 
overall expos\ire of harfufgl chemicals to consumers. Research studies have found harmful 
chemicals in the blood, uri!le and breast tumor tissue of study participants, but the research has 
not produced cohclusiyeevidence (1) of the source of the chemicals; (2) that the 
bioaccumulation of the chemicals has caused or will cause short-term or long-term harmful 
effects; or (3) that the chemicals directly cause cancer, birth defects, and other adverse health 
effects. The inconclusiveness of the research has led to ongoing controversy surrounding the 
safety of cosmetics. The Food and Drug Administration's (FDA) has oversight authority for 
cosmetic safety, yet its current legal authority is narrow and does not provide the oversight 
needed to mitigate the continual uncertainty related to cosmetic safety. FDA has no pre-market 
authority for cosmetic products, ingredients or labeling, with the exception of color additives. 
They assert that authorizing additional oversight would require legislative changes as well as 
additional fiscal and other resources. This paper argues the need for increased oversight and 
enforcement authority for the FDA, through statutory and regulatory changes, to ensure that 
cosmetics and personal care products are safe before they reach the shelves of wholesale and 
retail distributors. FDA must increase research efforts to determine the extent to which the 
ingredients in cosmetics contribute to adverse health effects. 
A literature review revealed that the FDA has no authority to require manufacturers to 
report ingredients used in cosmetic products. This serious limitation of FDA's oversight 
authority adds to the current debate and controversy surrounding three particular ingredients: 
phthalates, parabens and polycylic musks The concerns surrounding these three chemicals and 
others is so great, that two states, California and Washington have adopted legislation that 
provides their legislatures broader oversight authority as a means to improve safety of cosmetics 
and personal care products for their citizens. 
Introduction 
Millions of consumers throughout the world who use cosmetic products are reminded daily 
through various media that these products are associated with wealth, success and beauty. How 
these products are regulated differs from country to country. Consumers in the United States 
(U.S.) presume the ingredients in cosmetics and other personal care products are safe because the 
appropriate governing officials have approved the ingredients for use prior to the products being 
marketed to consumers. A review of the current U.S. statutes and regulations that govern 
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cosmetics safety reveals that federal officials have no authority over pre-market cosmetics, 
except for color additives and ingredients prohibited or restricted by regulation. While this 
paper is not intended to compare and contrast ingredient oversight of other countries with the 
U.S., it is important to note that the European Union (EU) prohibits or restricts 1100 toxic 
ingredients for use in cosmetics, while in the U.S.; the FDA prohibits or restricts only 11 
ingredients. The primary difference in oversight between the two countries is the definitions of 
cosmetics and drugs. Many cosmetic products in the U.S. are considered drugs in the EU (CSC, 
para. 3; Pauwels & Rogiers, 2004, p. 16). 
Consumer research organizations assert that the FDA does not understand the "scope and 
size of the potential health risks" from the ingredients found in many cosmetics (Houlihan, 
2008a, p. 5). The cosmetic industry contends that consumers "can be confident" that cosmetic 
products are safe due to the rigorous regulatory standards and enhanced manufacturing testing 
(Engasser, Long & McNamee, 2007, p. 30). 
Background 
As a public health agency, what is FDA's role in ensuring cosmetic safety? Let's first 
examine public health leadership, how it has evolved, the responsibilities and the expectations. 
The role of a public health leader may be described as the front-runner for securing a healthy 
population. Achieving a healthy population through monitoring, intervention, and prevention is 
a daunting task that requires the partnering of stakeholders, such as, a diverse groups of public 
health professionals, governmental officials (elected and appointed) at all levels (local, state and 
Federal), community and industry leaders, academia, foundations, consumer and research 
organizations, the media and members of the general population. 
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Public health leadership (PHL), like leadership in other sectors, is constantly evolving. A 
significant evolution in PHL carne with the Institute of Medicine's (IOM) 1988 Report on the 
Future of Public Health that painted a dismal picture of the state of public health. The IOM 
expressed grave concerns and argued that unless there was a new vision for public health, that 
the U.S. would be unable to meet the future health challenges of the nation. The IOM report 
(1988) noted that the "disarray" in public health was caused not only by the functioning of the 
public health system itself but also by the population's uncertainty of the mission of public 
health, the role of government to assure conditions in which people could be healthy, and 
inadequate resources necessary to achieve public health goals and objectives (pp. 6, 7). Willie 
PHL falls to governmental as well as non-governmental organizations, this discussion will focus 
of the role of government agencies. 
The IOM recognized the need for governmental and non-governmental efforts, but noted 
that the role of the government is "unique" (IOM eta!, 2008, p. 6). One unique aspect of the role 
of the government is its enforcement authority. In 1994, the Public Health Functions Steering 
Committee developed a framework for essential services: 
I. Monitor health status to identify community health problems 
2. Diagnose and investigate health problems and health hazards in the community 
3. Inform, educate, and empower people about health issues 
4. Mobilize community partnerships to identify and solve health problems 
5. Develop policies and plans that support individual and community health efforts 
6. Enforce laws and regulations that protect health and ensure safety 
7. Link people with needed personal health services and assure the provision of health care 
when otherwise unavailable 
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8. Assure a competent public health and personal health care work force 
9. Evaluate effectiveness, accessibility, and quality of personal and population-based health 
services 
10. Research for new insights and innovative solutions to health problems (Turnock, 2004, p. 
184) 
The evidence ofthe acceptance of the IOM report (Scutchfield, Hiltabiddle, Rawding and 
Violante, 1997) in the public health community can be found in agencies at all levels of 
government, universities, associations and others working to build a network of trained public 
health professionals and leaders capable of ensuring the delivery of the core functions. The 
Centers for Disease Control and Prevention's funding of the National Public Health Leadership 
Institute, beginning in 1990 (and continuing today) is but one example of the impact of the IOM 
report (NPHLI, 2009, para. 1 ). 
The role of PHL comes with tremendous responsibility and obligation. Rowitz (2009) 
argues that an effective public health leader must have the following prerequisites: "a 
commitment to social justice, an understanding of democracy, an understanding of the political 
process, communication skills, mentoring skills, decision-making skills, and the ability to 
balance work and like outside work" (p. 112). Turnock (2004) describes public health leadership 
as "an agent of social change by identifying health problems and risks and stimulating actions 
toward their elimination" (p. 234). These few simple words are the charge to take action for 
hundreds of thousands who make up the public health system. Identifying actual or potential 
health problems and then taking action to mitigate or eliminate the problems requires the 
engagement of most, if not all, stakeholders identified at the beginning ofthe leadership 
discussion. Stakeholders may come to the table with their individual agendas, and some, such 
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as elected officials, have more influence than others. Public health leaders must understand the 
positions of all stakeholders, whether in support of or against their efforts. This understanding 
provides the foundation for an effective strategy. "The leader needs two intellectual abilities that 
are usually not formally assessed in an academic way: he needs to have a sense for the 
unknowable and be able to foresee the unforeseeable" (Greenleaf, 1991, pp. 21-22). Despite the 
inevitable opposition of some stakeholders, public health leaders are servants of the population. 
They must be committed to the values and mission of the agencies they lead. There are two 
words that resonate in the mission statements of most if not all public health agencies, "protect 
and provide". 
FDA is a Federal agency under the purview of the Department of Health and Human 
Services. Its mission includes "protecting the public health by assuring the safety, efficacy, and 
security of human and veterinary drugs, biological products, medical devices, our nation's food 
supply, cosmetics, and products that emit radiation" (FDA, 2009,What We Do). FDA's role as 
a public health agency involves assuring conditions in which people can be health, ensuring that 
its decisionmaking is based on a public health perspective and not the perspective of the industry 
it regulates; and providing the public essential public health services. 
Literature Review 
The FDA administers the Federal Food, Drug and Cosmetics Act (FD&C Act) [regulatory 
authority granted to FDA]; and the Fair Packaging and Labeling Act (FPLA) [regulatory 
authority granted to Federal Trade Commission and FDA], two primary statutes that govern 
cosmetic safety. The FD&C Act, which was enacted in 1938, prohibits the marketing of 
adulterated and misbranded cosmetics. A product is considered adulterated if ( 1) it contains any 
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substances that cause harm to health when used as prescribed, or under customary use (except for 
hair dyes), (2) it consists "in whole or in part of any filthy putrid, or decomposed substance", (3) 
it has been contaminated, ( 4) its container contains substances that can cause harm to health, or 
(5) it contains a color additive (except for hair dyes) (FDA, 2005, para. 2). 
The Act defines cosmetics as "articles intended to be rubbed, poured, sprinkled, or sprayed 
on, introduced into, or otherwise applied to the human body or any part thereof for cleansing, 
beautifying, promoting attractiveness, or altering the appearance, and (2) articles intended for use 
as a component of any such articles; except that such term shall not include soap" (FD&C Act of 
1938). The definition is broad and includes products such as skin moisturizers, perfumes, 
lipsticks, fingernail polishes, eye and facial makeup preparations, shampoos, permanent waves, 
hair colors, toothpastes, and deodorants. 
Under, the FD&C Act, cosmetic products are considered mislabeled if the information 
contained on the labeling is false or misleading; the labeling does not include required 
information; required information does not display in a noticeable manner; its container is made 
in such a manner as to mislead the consumer; it is "a color additive, other than a hair dye, that 
does not conform to the applicable regulation issued under section 721 of the FD&C Act"; or 
the packaging and labeling is in violation of the Poison Prevention Packaging Act of 1970 
(FD&C Act of 1938). 
FDA's statutory authority for color additives is much broader, under the FD&C, "color 
additives, except for coal tar hair dyes", are required to be pre-approved by the agency before 
being used in "food, drugs, or cosmetics, or in medical devices that come in contact with the 
bodies of people or animals for a significant period of time" (FDA, 2010, para.!). 
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FDA's regulations permit the inspection of cosmetic manufacturing facilities, the collection 
of samples for examination and analysis, and regulatory actions against manufacturers that 
distribute adulterated and/or misbranded products. Cosmetic manufacturers are permitted to use 
any ingredient except for those ingredients in color additives or the 11 cosmetic ingredients 
which are prohibited or restricted by the FDA (Exhibit 1 ). 
The purpose of the FPLA is to inform the consumer by providing value comparison and to 
prohibit unfair and deceptive packaging and labeling of consumer goods. FDA administration of 
FPLA relates to packaging and labeling of foods, drugs, cosmetics and medical devices. The 
basic requirements of the FPLA include the (1) identification of the product, (2) the 
manufacturer's place of business and (3) the content in terms of net weight or number of items 
(FTC, Fair Packing). In more than three decades, the FDA has made no significant efforts to 
improve cosmetic safety through increased regulatory oversight. 
In 1974 the FDA established the Voluntary Cosmetic Registration Program (VCRP) as a 
voluntary registry program that applies to cosmetics sold in the United States. The VCRP 
collects data post-market, does not apply to cosmetic products for professional use only (salons, 
health care professionals, research and analysis), and does not apply to free gifts and samples or 
cosmetics made in an individual home to sell to friends. To register, a manufacturer provides the 
type and location of the business [the business trade names, type of business, address including 
post office zip code]; and/or product ingredient information. The registered information can be 
accessed electronically at the FDA website (FD&C Act of 1938). 
FDA's dictionary and product database report 4, 066 registered ingredients, while the 
Environmental Working Group (EWG) compiled a listing of ingredients for 29, 037 products 
found in its database with 8,821 unique ingredients. (EWG is a national non-profit organization 
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in Washington D.C. formed to protect public health and the environment. The group is one of the 
more vocal advocates of cosmetic safety issues.) The difference between the data shown in the 
two databases is 4,755 ingredients (Houlihan, 2008b, para. 25). Clearly, this difference raises 
questions of effectiveness of the VCRP. The program has no teeth. It is voluntary, without 
enforceable requirements, and no enforcement authority. 
The FD&C Act of 1938 was passed during a pro-industry period, when the United States was 
recovering from the Great Depression. The cosmetics industry was allowed to operate under a 
system of self-regulation, which illustrates the industry's level of influence on and the 
relationships with public health leaders and lawmakers at that time. Seventy-two years later, 
very little has changed with FDA's oversight and regulatory authority of the cosmetics industry. 
Some argue that FDA's longstanding incestuous relationship with the industry is the reason no 
change has occurred. Dickerson from Medical Device and Diagnostic Industry magazine (2010) 
writes, "Proindustry FDA culture is firmly entrenched. Not only is collaboration in product 
reviews officially encouraged, but good relationships across the regulatory fence hold the 
prospect of a possible future career in a well-paid industry job" (para. II). A limited review of 
industry placement of senior FDA officials immediately following their departure from the 
agency revealed the following: 
• John Bailey, former head of FDA's Office of Cosmetics and Color- Personal Care Products 
Council (Industry Association), Chief Scientist (PCPC, 2006) 
• Jane E. Henney, M.D., former FDA Commissioner (1117/1999 -1119/2001)- AstraZeneca 
(Pharmaceutical company), Board of Directors (FDA, 2009; AstraZeneca, 2009) 
• Daniel Schultz, former FDA Director of the Center for Device and Radiological Health-
Greenleaf, LLC, Senior Vice President (Dickerson, 20 I 0) 
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• Andrew C. von Eschenbach, M.D., Former FDA Commissioner (12/13/2006 -01/20/2009)-
Greenleaf, LLC (Regulatory Consulting Firm), Senior Advisor (FDA, 2009; Greenleaf, 
2009) 
This limited review is not an accusation or evidence of inappropriate relationships between 
the regulator and the industry, but it does raise questions concerning the influence former FDA 
senior officials could have on oversight and governance once they go to work in private industry; 
as well as current officials' ability to regulate a potential future employer. Similar relationships 
existed in the late 1980's with the Federal Home Loan Bank Board. Federal regulators' 
inappropriate relationships with the leadership of saving and loans banks led to the fall the 
Federal home loan bank system. However, FDA's relationship with the industry has deeper 
consequences because it can lead or has led to harmful health conditions in unsuspecting 
consumers. It can be argued that public health is founded in social justice (Tumock, 2004, p. 
14.), where the good of the society outweighs the need of an individual. In this instance social 
justice would argue that the FDA's relationship with the industry impedes its ability to advocate 
for the necessary oversight authority. 
Industry Voluntary Oversight 
Without federal authority to screen ingredients in cosmetics before they enter the market, 
the safety of cosmetics and personal care products falls to the industry that manufactures the 
products. In 1976, the cosmetic trade association, Cosmetic, Toiletry and Fragrance Association, 
now known as the Personal Care Products Council (PCPC) established a voluntary industry 
program, the Cosmetic Ingredient Review (CIR) to determine whether ingredients are safe under 
the conditions of use. CIR is comprised of expert panelists from private and public sectors 
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(CIR, 2009, Procedures). The CIR review process and findings are purported to be independent 
of the PCPC and the cosmetic industry (CIR, 2008 Annual Report), however the CIR is funded 
by PCPC. During the CIR's thirty plus years of operation, they have only reviewed 16 percent 
of the ingredients in products. CIR reviews found I 067 ingredients safe, 446 safe with 
qualifications, 10 unsafe and insufficient data on 124 ingredients (CIR, 2010, Cosmetic 
Ingredients). Dr. Bailey noted while serving as the head of the FDA's Office of Cosmetic and 
Color that, "In the absence of the CIR program, there would be no systematic examination of the 
safety of individual cosmetic ingredients" (Houlihan, 2008a, para. 9). The CIR has 
recommended restrictions on chemicals beyond those identified by FDA and has identified an 
additional I 0 ingredients as unsafe for use in cosmetics (Exhibit 2). 
Growing Debate and Continued Controversy 
FDA and CIR together have restricted or prohibited only 21 (Exhibit 1 and 2) of the 
thousands of chemicals found in cosmetic products. The industry maintains that the exposure 
level of these potentially harmful chemicals is minimal while consumer groups and some 
government officials continue to raise concerns surrounding the bioaccumulation of these 
chemicals, and their potential long-term impact on human health. On average, adults use 9 
personal care products daily, with 126 unique chemical ingredients (EWG, 2004, para. 1). 
The fact that only 16 percent of ingredients in cosmetics have been reviewed by a voluntary 
body and of that percentage only 21 ingredients have been prohibited for use raises significant 
questions about FDA's commitment to the core functions of public health. Several of the 
Essential Services for Public Health as presented in the role of public health leadership section of 
the paper, suggest that public health agencies and private sector providers should empower the 
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public on health issues; use scientific knowledge as the basis for decision-making; and assure the 
public of the commitment to their needs, through various policy making and enforcement tools. 
FDA contends that they are limited by the requirements of the FD&C Act; however, there is no 
evidence that FDA has aggressively partnered with Congress to seek broadening of its oversight 
authority. 
CDC's National Health and Nutrition Examination Survey (NHANES) is a good reference 
point for data and statistics on the health of the public. NHANES was established in 1960 and is 
used as a tool to gather data on the health and nutrition of adults and children in the U.S. The 
survey is administered through interviews and physical examinations. The interviews include 
questions on health matters, and "demographic, socioeconomic and dietary" status; and the 
physical examination includes "medical, dental, and physiological measurements" and 
"laboratory tests". (CDC, 2009, NHANES, para. 1, 3.) This survey provides the essential 
services of monitoring and detecting health hazards through surveillance. 
The CDC's 2009 Fourth National Report on Human Exposure to Envirornnental 
Chemicals reports on the findings of the NHANES during 2003 and 2004, and provides a period 
in time assessment of the public's exposure to envirornnental chemicals. The report also 
includes some results from prior surveys (years 1999-2000 and 2001-2002). The 2003- 2004 
survey included more than 2600 participants (aged 6 years and older) and measured 13 
phthalate metabolites [metabolite is a chemical alteration of the original compound produced by 
body tissues.] in the urine and/or blood samples of the participants (CDC, Fourth National 
Report, p. 3 ). CDC contends that biomonitoring data alone does not indicate that the chemicals 
found cause disease or harm to human health; and that research separate from the report is 
required to determine if the chemical exposure levels can be associated with disease and adverse 
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health effects. Biomonitoring is "the direct measurement of people's exposure to toxic substances 
in the environment by measuring the substances or their metabolites in human specimens, such 
as blood or urine" (CDC, National Biomonitoring Program, para. 1). CDC selects chemicals for 
the report based on the following criteria: 
• Existing research and scientific data on environmental chemical exposure 
• The severity of known or suspected health effects due to the exposure 
• The "need to assess the efficacy of public health actions to reduce exposure to a chemical" 
• The availability of a biomonitoring analytical method with adequate accuracy, precision, 
sensitivity, specificity, and speed 
• The availability of sufficient quantity of blood or urine samples 
• The incremental analytical cost to perform the analyses" (CDC, Fourth National Report, p. 
4) 
A review of CDC's Fourth National Report revealed at least six chemicals commonly 
found in cosmetics and personal care products. While the NHANES report provides extensive 
details regarding each chemical, this paper only includes a listing of the six chemicals identified 
in the report as used in cosmetics (Exhibit 3). While it is true that there are several ingredients in 
cosmetics that are of considerable concern, there are three particular ingredients that are the 
subject of significant and heated debate and controversy: phthalates, parabens and polycylic 
musks. Of these three chemicals, only phthalates is mentioned in the NHANES report. 
The Breast Cancer Fund, 2008 Edition of the State of Evidence, The Connection Between 
Breast Cancer and the Environment, presents illuminating research findings on the link between 
radiation and chemicals in the environment to the rate of breast cancer. The report summarizes 
findings of over 400 epidemiological and experimental studies, and echoes the same policy concern 
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as so many other consumer and research organizations. That is, there is no Federal authority to 
pre-screen ingredients before most cosmetic products are marketed, and the lack of Federal 
oversight authority places the general public at health risk. While the State of Evidence 
addresses a broad range of chemicals contributing to the current breast cancer rate, this paper 
will only focus on the chemicals found in cosmetics and personal care products, specifically 
those chemicals classified as endocrine-disrupting compounds (EDCs) (BCF, 2009). 
The State of Evidence discusses the 2007 Silent Spring Institute's review and analysis of 
epidemiological data to find evidence of a link between certain chemicals and breast cancer 
rates. It is generally accepted that exposure to natural estrogen may increase the risk of breast 
cancer. Xenoestrogens, synthetic agents that mimic the actions of estrogen, are one type ofEDC 
but others may "disrupt normal biological processes by disturbing not only the actions of the 
estrogens, but also those of other hormones including the androgens and thyroid hormone. All of 
these disruptions may increase the risk for breast cancer" (BCF, 2009, p. 8). EDCs can be found 
in a host of pesticides, fuels, plastics, detergents, industrial solvents, tobacco smoke, prescription 
drugs, food additives and personal care products (Hormonally Active Agents, 1999; 
Environmental Pollutants, 2003). Phthalates and parabens were specifically named in the report 
as EDCs found in cosmetics and personal care products. Phthalates are plasticizers and are found 
in such products as skin moisturizers, nail polish, and hair sprays, and are classified as EDCs 
because of their effects on the hormonal system. Research has shown that some phthalates can 
alter cell culture systems, "increase cell proliferation in MCF-7 breast cancer cells and .. .inhibit 
the anti-tumor action oftamoxifen in MCF-7 breast cancer cells" (BCF, 2009, pp. 49, 50). 
Parabens are preservatives and are classified as EDCs because they have been found to be a 
"weak estrogen mimicker and cause human breast tumor cells (MCF-7 cells) to grow and 
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proliferate in vitro" (BCF, eta!, 2009, p. 50). Parabens are used in cosmetics including such 
products as underarm deodorants, hair products, and shaving creams. Several types of parabens 
have been found in samples from breast tumors. 
Neither the National Toxicology Program nor the National Cancer institute (National 
Institute of Health); or the International Agency for Research on Cancer (The World Health 
Organization) have deemed EDCs as human carcinogens. There is a body of research on wildlife 
species that shows a causal relationship, but research on humans is less conclusive (BCF, 2009, 
p.37). The FDA acknowledges their awareness of consumer concerns with these chemicals but 
note at current they [FDA J find no safety risk (FDA, 2000, Ingredients Prohibited). 
On December 2, 2009, the Senate's "Full Committee and Subcommittee on Superfund, 
Toxics and Environmental Health joint hearing entitled, "Oversight Hearing on the Federal 
Toxic Substances Control Act" heard testimony on the amount and level of industrial chemicals 
that can be found in the human body. During the hearing, Senator Frank R. Lautenberg, 
mentioned the findings of the Environmental Working Group's (EWG) December 2, 2009 
Report on "Pollution in People". The EWG reported that a 2-year study (2007 and 2008) found 
over 200 chemicals in the umbilical cord blood of 10 babies from racial and ethnic minority 
groups (Lautenberg, 2009). The findings from the research revealed that infants are exposed to 
hazard chemicals through the placenta prior to birth. The chemicals Tonalide and/or Galaxolide 
(polycyclic musk) which are ingredients of cosmetics and personal care products were found in 7 
of 10 cord blood samples tested. These chemicals are synthetic fragrances used to mimic 
natural musk (EWG, 2009, p. 22). The report notes that the health risks to humans are unknown 
but that a few studies suggest that these chemicals "disrupt hormones" and "damages organisms' 
defense" (EWG, et a!, 2009, p. 22). 
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The NIEHS reports that polycyclic musk presents a concern for bioaccumulate but the 
toxicity and enviromnental risk of the chemical is low. However, NIEHS also notes that there is 
evidence to support the effects this chemical has on marine mussels but not on human health 
(Nitromnusk and Polycyclic, 2004). It [polycyclic musk] interferes with the activity of their 
multidrug efflux transporters. Cells naturally resist toxicants through the transporters, "proteins 
that keep foreign chemicals from entering cells" (Whiff of Danger, 2005. p. A50). There is 
concern that these findings could translate to human health, that medications (pharmaceuticals) 
and other chemicals (not naturally produced) could cause similar long-term effects in humans. 
John Bailey, Chief Scientist for the Personal Care Products Council (PCPC) and former 
head of FDA's Office of Cosmetics and Color, provided testimony at the hearing and contends 
the fragrances used in cosmetics and personal care products are safe and are regulated by the 
FDA. PCPC, originally founded in 1894 as the Manufacturers Perfumes' Association of the 
United States, is a leading national trade association for the cosmetics and personal care products 
industry (PCPC, Centennial History). Dr. Bailey argued that the detection of chemicals in a 
human body through the process of biomonitoring is not proof that a person has been exposed to 
a toxic level of the chemicals (Bailey, 2009). He supported the industry's position with a quote 
from the Centers for Disease Control and Prevention's, "Interpretation of Report Data, Important 
Factors" which states "The measurement of an enviromnental chemical in a person's blood or 
urine does not by itself mean that the chemical causes disease" (CDC, Fourth Annual Report, p. 
viii). 
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Efforts to Improve Product Saftty and to Inform the Public 
In the absence ofF ederal authority to pre-market cosmetic products, some States, consumer 
groups, and the industry itself have taken steps to improve product safety. The efforts on part of 
the states should not come as a surprise because state public health leaders and professionals play 
an essential role in implementing public health policies and programs. The U.S. Constitution 
vested in the States primary responsibility for the health care of its population. The IOM stated 
that " ... states are and must be the central force in public health" (IOM, 1988, p. 8). Federal 
agencies and the legislative branch of government pass statutes, promulgate regulations and 
develop Federal programs. State public health agencies monitor the effectiveness oflocal public 
health delivery systems. Local public health agencies (LPHA) are responsible for ensuring that 
health problems are monitored and that mitigating services are available. LPHAs are on the 
frontline. State and Local government actions have been significant in mitigating health 
concerns such as tobacco use reduction, reduction in teenage pregnancies, adolescent 
vaccinations, etc. 
This unique system is often confusing to the public due to the involvement of all levels of 
government. An example is the Special Supplemental Nutrition Program for Women, Infants 
and Children (WI C) administered at the Federal level by the Food and Nutrition Service (FNS), 
United States Department of Agriculture. The program's funding is authorized annually by 
Congress via Federal grants. FNS provides the funding to all 50 states for the purchase of"WIC 
foods, nutrition education, breastfeeding promotion and support and administrative costs" 
(USDA, 2009, para. 2). At the state level the program is administered using 90 WIC state 
agencies, 2,200 local agencies and 9,000 clinic sites (USDA, 2009, para. 3). 
17 
State Efforts 
The states of California and Washington have recently passed legislation designed to 
improve the safety of cosmetics and personal care products. The California Safe Cosmetic Act 
of2005, effective January 2007, requires manufacturers to report to the California Department of 
Health Services (DHS) use of potentially hazardous ingredients and to submit health effects data. 
This is in contrast to the FDA's voluntary registration program. The bill also grants the DHS' 
Division of Environmental and Occupational Disease Control investigatory authority. The 
division may conduct an investigation of products that contain chemicals identified as causing 
"cancer or reproductive toxicity or other ingredients of concern" (CSC Act of2005, p.92). The 
California bill highlights several significant facts and points: 
• Independent testing in the United States and abroad revealed some cosmetic products 








Like FDA's authority, pre-market safety screening is not authorized in the Bill 
Like FDA's authority, prior approval of ingredients is not authorized in the Bill 
The Bill does not authorize DHS the authority to regulate ingredients in cosmetic products 
Women of childbearing years have the greatest percentage of product usage 
Beauty care workers are the most exposed population 
Ingredients used in fragrances are exempt from inclusion of product labeling 
The Division of Environmental and Occupational Disease Control in DHS may conduct 
workplace investigations and analysis 
• Safe ingredients are available for use as substitutes for harmful chemicals 
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While this Bill does not grant the state authority to regulate ingredients in cosmetic it does 
require the manufacturer to report harmful ingredients and their health effects. This reporting is 
the first step in assisting the state in informing and educating its citizen of the potentially harmful 
ingredients in certain cosmetic products. The legislation was sponsored by the National 
Environmental Trust, Breast Cancer Action, and Breast Cancer Fund. Kevin Reilly, DHS, Deputy 
Director of Prevention Services, indicated that the "Legislation sponsors believe that the basis of 
the law is the public's right to know" (California Enacts, 2006, para. 2). California's partnering 
with consumers and advocates to address the shortcomings of the FD&C Act; and the health 
concerns of its citizens led to the passing of the CSC Act of2005. The state of California 
exercised its authority to provide assurance (core function of public health) to the people of the 
state by taking positive steps to ensure safety of cosmetic products sold and used; and to mitigate 
the health risk of its citizens, particularly, women of childbearing age, children and employees of 
nail and beauty salons (CSC Act of2005). The California Cosmetic Safety Program (CCSP) 
administered by the California Department of Public Health has established online reporting of 
chemicals known to or suspected of causing cancer and/or reproductive toxicity from companies 
making $1,000,000 or more from California consumers and/or other states (effective January 
2007 (CDPH, 2009, para. 1.). CCSP plans to make the reported information available to the 
public so they may make informed decisions prior to the purchase of cosmetics (CCPH, 2009, 
What's New). 
The Bill met opposition by the industry, particularly, Procter & Gamble (P&G) and PCPC. 
Salgado (2006) reports that P&G paid lobbyists over $90,000 in the first half of 2005, and PCPC 
spent more than $600,000 in the last two legislative sessions to kill the Bill (Salgado, 2006, para 
1-2). California's strategic partnering can serve as a model for states as well as FDA. 
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The only other state to pass legislation to increase cosmetic safety is Washington. In 2008, 
the state of Washington passed the Children's Safe Products Act (CSPA), effective July 1, 2009. 
This Bill, known as the Toxic Toy, is aimed at the safety of products for kids and it imposes 
stricter standards on manufacturing reporting than the Consumer Product Safety Improvement 
Act (CPSIA) signed by President George W. Bush in August 2008. Washington's CSPA 
included products such as children's cosmetics, jewelry, toys, products for sucking, teething, or 
to facilitate sleep, and children electronic products. The Act: 
• Prohibits the manufacture and sale of children products containing lead, or cadmium 
• Requires the Washington State Department of Ecology to identify and report high priority 
chemicals 
• Requires manufacturers of children's products report annually on products containing high 
priority chemicals 
• Requires manufacturers of products that become restricted by law to notify sellers of the 
requirements ofthe law; recall the products and reimburse the sellers and any purchasers of 
the product 
• Violators of the Bill are subject to civil penalties up to $5000 for each violation on the first 
offense. Thereafter, violators are subject penalties up to $10,000 for each offense (CSC Act 
of2005) Children's cosmetics and car seats are not covered in the Federal CPSIA, but are 
included in Washington State's law. 
Washington's partnering effort is another excellent example of the state fulfilling its 
assurance function and strategic partnering. Washington understands the significance of 
influence and relationships in policymaking. The lead sponsor of its Bill was Representative 
Mary Lou Dickerson (D-Seattle), supported by Washington's the health care practitioners. Dr. 
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Richard Grady, MD, pediatric urologist and board member of Washington Physicians for Social 
Responsibility, stated "We have a responsibility to ensure that our children's minds and bodies 
do not bear the burden of damage from toxic chemicals in any product, and especially 
toys .. .legislative action is a victory for children's health and futures" (Valeriano, 2008, p. 1,7). 
Industry and Consumer Groups Efforts 
Skin Deep, a cosmetic safety database developed by EWG provides consumers and the 
industry with vital information on cosmetic products, their ingredients, toxicology and health 
concerns related to the ingredients. Regulatory classification of ingredients if known is included 
in the database. Regulatory information is not limited to the U.S.; Skin Deep contains publicly 
available information from regulatory bodies throughout the world. The database contains over 
25,000 products (EWG, Skin Deep). 
In January 2007, the Personal Care Products Council (PCP C) established a Consumer 
Commitment Code (CCC) to provide assurance to consumers and state and federal regulators of 
the industry commitment to the safety of cosmetic and personal care products. Regrettably, the 
CCC does not impose any requirements; all actions so noted in the CCC are voluntary (Exhibit 
4). 
The Compact for Safe Cosmetics (CSC) is also partnering with the cosmetic industry. 
The CSC has agreed to assist and support their industry partners to educate and inform 
consumers. To meet CSC's commitment agreement, signers must (1) comply with the U.S. 
regulatory requirements for cosmetics and the EU Cosmetic Directive; (2) disclose all 
ingredients of all cosmetic products; (3) utilize EWG'S Skin Deep database for publishing 
product information; ( 4) comply with ingredients prohibitions and restrictions and use safer 
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available ingredients; (5) demonstrate the safety of the products using data that is available to the 
public; and (6) actively participate in CSC's efforts. Over 1400 companies have taken the pledge 
(CSC, Compact for Safe Cosmetics). 
Retailers have also joined the effort to increase product safety. In 2008, Whole Foods 
Market and CVS (largest U.S. Drug Store Chain) committed to safer ingredients by banning 
cosmetic products that contain certain ingredients. Whole Foods has identified over 3 00 
ingredients that are considered unacceptable, including parabens, polypropylene and 
polyethylene glycols, sodium Iaury! and laureth sulfates. These ingredients serve as 
preservatives, cleaners and conditioners and fragrances. Whole Foods conducted three years of 
scientific research and found some adverse effects from use of products containing these 
ingredients. Whole Foods list goes beyond the requirements of FDA and CIR (WFM, 2008). 
CVS has harmed hexachlorophene, mercury compounds, chloroflourocarbons, bithionol, 
chloroform, halogenated salicylates, vinyl chloride, zirconium and methylene chloride. All but 
one of CVS 's harmed ingredients are prohibited or restricted by the FDA (CVS, Cosmetics and 
Personal Care). 
Method 
The literature search on cosmetic safety concerns began with the NIEHS website and their 
Community Outreach & Education Program online lesson: Beauty or the Beast? This lesson 
referenced related articles and provided website links to several public and private sector 
resources including but limited to the FDA, the Campaign for Safe cosmetics, the Environmental 
Working Group, EHP articles, California's Department of Public Health and more. Key search 
words from selected from this lesson included: safety of personal care products, chemicals used 
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in cosmetics, harmful health conditions from cosmetic ingredients, FDA, FDA's relationship 
with the cosmetic industry and Congress and cosmetic safety. 
Research data on chemicals found in humans was found from the Centers for Disease 
Control and Prevention, National Institute of Health, the Enviromnental Working Group, and the 
Breast Cancer Fund. General searches were conducted in the University of North Carolina's and 
CDC's e-libraries for findings published during the past 5 years. 
Research data on chemicals used in cosmetics and product information was obtained from 
the FDA, CIR, Skin Deep database and NIH. General internet searches were conducted through 
Google, Google Scholar, and Yahoo and CDC intranet/internet. 
Research pertaining to the cosmetic safety oversight was found from FDA, the 
National Archives and Records Administration and a general internet search using Google, 
Google Scholar and Yahoo. 
Conclusion 
FDA's oversight authority is narrow and lacks efficacy in vital areas of cosmetic safety, 
precmarketing of products, ingredients and labeling. Their VCRP has yielded disappointing 
results and is over shadowed by Skin Deep. The well documented longstanding relationship 
between the FDA and the cosmetics industry as well as the pilfering of FDA executives to 
industry leadership positions sharply conflicts with the core principles of public health 
leadership. Public health leaders, unlike the leaders in industry, pledge a commitment to 
safeguard the health and well being of the public. FDA appears to have lost sight of that pledge 
and their mission. They argue that their authority is limited and resources are insufficient to 
address the needed oversight. The FD&C Act was enacted 72 years ago and to date there have 
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been very few amendments. Meanwhile, there is no evidence that FDA has made appreciable 
efforts to partner with consumers, advocacy groups or the industry to introduce effective 
legislation that would strengthen their oversight authority. It could be argued that FDA desires 
not to disrupt their current relationship with the industries they regulate in spite ofthe fact those 
relationships impede their ability to be effective public health leaders. 
The battle for improved cosmetic safety has fallen to the non-regulators. Over the past five 
years, consumer groups and the cosmetic industry have sought improved product safety through 
voluntary commitment to safe product programs, and have called for greater regulatory authority 
and increased research by public health officials. Scientific research continues to raise more and 
more questions about the bioaccumulation and the long-term effects environmental chemicals 
will have on human health. To date there is no conclusive scientific evidence that directly links 
chemicals found in cosmetics to harmful health effects. Federal public health officials at the 
CDC, NIH and FDA have acknowledged that additional research is necessary. 
The IOM 1988 report marked a new, different and well needed strategic direction for public 
health but there is little or no evidence that FDA is supportive of the new approach. In fact, 
some may argue that their limited regulatory and policies changes in cosmetic safety over the 
past decades is a reflection of their indifference with the IOM 1988 recommendations. HHS, 
FDA and Congress must be held accountable for assuring the public that FDA bases its 
decisionmaking on a public health perspective, and that the agency embraces the core principles 
of public health by providing the public needed essential services. During the past two years 
Congress has convened hearings to explore concerns raised by consumer and research groups 
about chemical used in cosmetics and personal care products. FDA's leadership has an 
obligation to ensure the agency provides conditions for a healthy public; through ongoing 
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evaluations of its cosmetic safety authority compared to its mission, seek external input from 
stakeholders, proactively achieving corrective remedies (increased oversight and scientific 
research) and conduct continual program evaluations to ensure programs are meeting the public 
health needs of the nation. 
Recommendations 
Ensuring cosmetic safety is complicated and there is no quick fix. FDA leadership must 
take necessary steps to assure the public that the agency is grounded in the principles of public 
health. They can begin the process of assurance by considering the following recommendations: 
o Consumer Education: The vast majority of the U.S. consumer presumes cosmetic products 
are safe and proved by Federal officials. Public notice of product information must be 
provided to the consumer prior to the purchase on a cosmetic product. The industry must be 
required to educate consumers using all media forums currently used to advertise their 
products (TV commercials, magazines, in-store posters, newspaper, leaflet and brochures 
past along with free samples, etc.). A well performing public health system would be 
informing, educating, and empowering people about health issues. An example of an 
evidence-based intervention for educating and empowering is reducing the use of tobacco. 
The CDC reported in 2000 that "educational strategies, concluded in conjunction with 
community- and media-based activities, can postpone or prevent smoking onset in 20 to 40 
percent of adolescents" (para. 17). 
• Establishment of a Federal advisory committee or board to provide advice and 
recommendations to FDA and HHS on policy and scientific matters relating to cosmetic 
safety including recommendations for industry requirements and additional research. The 
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committee would be comprised ofF ederal officials from various public health and 
environmental agencies, industry and academic experts as well as public members. This 
body would report to the FDA Administrator, hold meetings open to the public and publish 
periodic consumer reports. FDA has similar committees for food and drug safety: Drug 
Safety and Risk Management Advisory Committee and the Food Advisory Committee. This 
strategy provides the agency's leadership an opportunity to partner with the community in 
identifying and solving health problems. 
• Policy Development and Enforcement Authority: FDA's cosmetic safety mission is limited 
by existing laws. The FD&A must be broaden to include mandatory manufacturers 
registration, pre-marketing (products, ingredients and labeling screening) authority and fiscal 
resources to support and the publication of manufacturers ratings based on the safety of their 
ingredients. California and Washington have provided excellent examples of how partnering 
with multiple stakeholders resulted in progressive legislation and policies focused on meeting 
the health needs of the community. The state changes would not have been possible without 
its leadership involvement, from the public health agencies to state Congressional 
representatives. FDA must use similar leadership strategies in developing its public health 
policies so to assure the public that the agency is addressing and supporting their health 
efforts and concerns. 
• Increased Research: The current debate on cosmetic product safety is stemmed from the 
inconclusive scientific evidence surrounding chemicals found in cosmetics and 
bioaccumulation, the long-term effect of environmental chemicals to human health. Federal 
officials and consumer group repeatedly stressed the need for additional research. The 
research is essential in determining the long-term effect of chemicals already found in human 
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blood and urine samples. The tenth essential public health service involves research that 
leads to innovative remedies to health concerns and problems. As an HHS agency, FDA has 
the support of its sister agencies, CDC and NIH. Research collaborations between these 
agencies may yield the conclusive scientific evidence for linking or not linking ingredients in 
cosmetics to harmful health conditions. The partnering of these agencies can ease FDA's 
Federal funding burden and increase the private sector stakeholder base capable of producing 
creditable research findings. 
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Bithional The use ofbithionol is prohibited because it may cause photo-contact sensitization (21 CFR 
700.11) 
Chlorofluorocarbon The use of chlorofluorocarbon propellants (fully halogenated chlorofluoroalkanes) in 
propellants cosmetic aerosol products intended for domestic consumption is prohibited. Ozone 
depletion. (21 CFR 700.23) 
Chloroform The use of chloroform in cosmetic products is prohibited because of its animal 
carcinogenicity and likely hazard to human health. The regulation makes an exception for 
residual amounts from its use as a processing solvent during manufacture, or as a byproduct 
from the synthesis of an ingredient (21 CFR 700.18) 
Halogenated These are prohibited in cosmetic products because they may cause photocontact 
salicylanilides sensitization (21 CFR 700.15) 
Hexachlorophene Because of its toxic effect and ability to penetrate human skin, hexachlorophene (HCP) may 
be used only when an alternative preservative has not been shown to be as effective. The 
HCP concentration of the cosmetic may not exceed 0.1 percent. HCP may not be used in 
cosmetics that in normal use may be applied to mucous membranes, such as the lips [21 
CFR 250.250] 
Mercury Mercury compounds are readily absorbed through the skin on topical application and tend to 
accumulate in the body. They may cause allergic reactions, skin irritation, or neurotoxic 
manifestations. The use of mercury compounds as cosmetic ingredients is limited to eye area 
cosmetics at concentrations not exceeding 65 parts per million (0.0065 percent) of mercury 
calculated as the metal (about 100 ppm or 0.01 percent phenylmercuric acetate or nitrate) 
and is permitted only if no other effective and safe preservative is available for use. All 
other cosmetics containing mercury are adulterated and subject to regulatory action unless it 
occurs in a trace amount ofless than I part per million (0.0001 percent) calculated as the 
metal and its presence is unavoidable under conditions of good manufacturing practice [21 
CFR 700.13] 
Methylene The use of this substance in cosmetic products is prohibited because of its animal 
Chloride carcinogenicity and likely hazard to human health (21 CFR 700.19) 
Prohibited cattle To protect against bovine spongiform encephalopathy, also known as "mad cow disease," 
material cosmetics may not be manufactured from, processed with, or otherwise contain, prohibited 
cattle materials. These materials include specified risk materials; material from 
nonambulatory cattle, material from cattle not inspected and passed, or mechanically 
separated beef. Prohibited cattle materials do not include tallow that contains no more than 
0.15 percent insoluble impurities, tallow derivatives, and hides and hide-derived products, 
and milk and milk products. [21 CFR 700.27, as amended] 
Sunscreen in Use of the term "sunscreen11 or similar sun protection terminology in a product's labeling 
cosmetics generally causes the product to be subject to regulation as a drug. However, sunscreen 
ingredients may also be used in some products for nontherapeutic, nonphysiologic uses (for 
example, as a color additive or to protect the color of the product). To avoid consumer 
misunderstanding, if a cosmetic product contains a sunscreen ingredient and uses the term 
"sunscreen" or similar sun protection terminology anywhere in its labeling, the term must be 
qualified, in accordance with 21 CFR 700.35(b), by describing the benefit to the cosmetic 
product provided by the sunscreen ingredient. Otherwise, the product may be subject to 
regulation as a drug [21 CFR 700.35] 
Vinyl Chloride The use of vinyl chloride is prohibited as an ingredient of aerosol products, because of its 
carcinogenicity [21 CFR 700.14] 
Zirconium- The use of zirconium-containing complexes in aerosol cosmetic products is prohibited 















Reproductive and Developmental Toxicity 
Carcinogenicity 





Carcinogenicity (unsafe for leave-on products, insufficient data for hair 
dyes) 
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Acrylamide Small organic molecule existing as a white crystalline powder in International Agency for 
its pure state. Commercially, acrylamide is synthesized and used Research of Cancer (!ARC) 
in the production of polyacrylamide polymer, gels, and binding classifies acrylamide as 
agents. Polyacrylamides are useful water-compatible polymers probably carcinogenic to 
used in water treatment, mineral processing, pulp and paper humans. 
production, and in the synthesis or compounding of dye 
materials, soil conditioners, and cosmetics 
Benzophenone It is commercially synthesized as a sunscreen for use in lotions, !ARC and National 
- 3 (2-hydroxy- conditioners, and cosmetics. It is also used as a UV stabilizer in Toxicology Program (NTP) 
4- plastic surface coatings and polymers. have no ratings as to human 
methoxybenzo carcinogenicity of 
phenone) benzophenone-3. 
Lead Less common sources of incidental or unique lead exposure are !ARC considers inorganic 
numerous: lead-glazed ceramic pottery; stained glass framing; lead compounds probable 
pewter utensils and drinking vessels; older plumbing systems human carcinogens, and 
with leaded pipes or lead soldered connections; lead-based organic lead compounds not 
painted surfaces undergoing renovation or demolition; imported classifiable with respect to 
children's trinkets and toys; lead-containing folk and remedies human carcinogenicity. 
and cosmetics. NTP considers lead and its 
compounds reasonably 
anticipated to be human 
carcinogens. 
Phthalate Phthalates are industrial chemicals that are added to plastics to The NTP's Center for the 
impart flexibility and resilience and are often referred to as Evaluation of Risks to 
plasticizers. There are numerous products that contain phthalates: Human Reproduction has 
adhesives; automotive plastics; detergents; lubricating oils; some reviewed the developmental 
medical devices and pharmaceuticals; plastic raincoats; solvents; and reproductive effects of 
vinyl tiles and flooring; and personal-care products, such as soap, specific phthalates. 
shampoo, deodorants, lotions, fragrances, hair spray, and nail 
polish. 
Benzyl butyl Benzylbutyl phthalate (BzBP) is a solvent and additive used in !ARC considers BzBP not 
Phthalate products such as adhesives, vinyl tile, sealants, car care products, classifiable with respect to 
and to a lesser extent, some personal care products. human carcinogenicity. 
Di-n-butyl Industrial solvents or additives used in many personal care Neither !ARC nor NTP has 
Phthalate products such as nail polish and cosmetics, and also in some evaluated dibutyl phthalates 
Di-isobutyl printing inks, pharmaceutical coatings, and insecticides. with respect to human 
Phthalate carcinogenicity. 
4-tert- 4-tert-Octyphenol, an alkylphenol, is used to manufacture !ARC and NTP have not 
Octylphenol alkylphenol ethoxylates, which are anionic surfactants used in rated octylphenol, 
detergents, industrial cleaners, and emulsifiers. Commercial nonylphenol, or their 
formulations of alkylphenol ethoxylates usually contain a mixture corresponding ethoxylates 
of oligomers and isomers, and the polyethoxy chain may consist with respect to human 
of up to 50 ethoxy units. Less frequently, the various carcinogenicity. 
alkylphenols have also been used as emulsifiers and modifiers in 
paints, pesticides, and some personal care products. 
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The Personal Care Products Council Consumer Commitment Code 
Preamble 
Exhibit 4 
Cosmetic products are the safest products regulated by the U.S. Food and Drug Administration (FDA), a fact that has been 
recognized by a number of FDA Commissioners over the last several decades. 
To further strengthen industry safeguards for consumers, the Personal Care Products Council has instituted a Consumer 
Commitment Code for the cosmetic industry. This incorporates and strengthens some practices already in place for most 
companies, such as the current reporting of manufacturing establishments; and it includes new practices such as a Safety 
Information Summary Program that makes information relevant to cosmetic product and ingredient safety readily available to the 
FDA upon request. 
The Council's Board of Directors unanimously supports the principles and practices embodied in this Code. It will formally take 
effect for all Council members on January 1, 2007. Throughout 2006, the Council will commit substantial resources to educating 
its members on the practices embodied in the Code and gaining their commitments to the Code. The Council will also reach out 
to many related trade associations and other organizations to encourage broad recognition of the Code by 2007. 
During this time, we will continue to work closely with the Food and Drug Administration to provide as much information 
regarding cosmetic safety as the agency needs to evaluate the safety of the products. In providing FDA with access to this 
information we seek to provide consumers with the continued confidence that the proper-steps are being taken by government 
and industry to assure the continued safety of all cosmetic products, and to allow consumers to make fully informed choices 
when purchasing cosmetic products. 
The Personal Care Products Council Consumer Commitment Code 
The following principles constitute the Personal Care Products Council Consumer Commitment Code: 
1. A company should market cosmetic products only after ensuring that every ingredient and finished product has been 
substantiated for safety. The decision that an ingredient has been substantiated for safety may be based on a finding by the 
Cosmetic Ingredient Review Expert Panel that such ingredient is safe for the use intended by the company or on other 
appropriate data and information. 
2. When marketing a cosmetic product containing an ingredient that exceeds limits on concentration or product type 
established by the Cosmetic Ingredient Review Expert Panel, a company should possess information sufficient to 
substantiate the safety of the ingredient for its intended use in such product and be willing to make that information available 
for inspection by the Food and Drug Administration. 
3. When marketing a cosmetic product containing an ingredient for which the Cosmetic Ingredient Review Expert Panel 
has found insufficient data to detennine safety, a company should possess information sufficient to substantiate the safety of 
the ingredient for its intended use in such product and be willing to make that information available for inspection by the 
Food and Drug Administration. 
4. A company should participate in the applicable parts of the FDA Voluntary Cosmetic Reporting Program set forth in 21 
CFR Parts 710 and 720 for products marketed in the United States, and file timely reports regarding its manufacturing 
establishments and ingredient usage. 
5. Although adverse events that are both serious and unexpected are extremely rare for cosmetic products, a company 
should notify the Food and Drug Administration of any known serious and unexpected adverse event as a result of the use of 
any of its cosmetic products marketed and used in the United States. "Serious" and "Unexpected" are defined in accordance 
with FDA's definition for such experiences related to drugs in 21 CFR 314.80(a). Information related to other product 
experiences as described in the Council's Safety Information Summary Program should be maintained in the safety 
information summary described in Paragraph 6 below. Such information should be made available for inspection by FDA 
under the conditions specified in that program. 
6. A company should maintain a safety information summary of ingredient and product safety information and data 
regarding its cosmetic products marketed in the United States as specified in the Council's Safety Information Summary 
Program Guideline, and make any information in that safety information summary available for inspection by FDA under 
the conditions specified in that program. (PCPC, Commitment Code) 
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